Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
Istradefylline (KW-6002) is one of many xanthines that act as antagonists of the A2A adenosine receptor (A2AR). While this molecule has recently been involved in phase III clinical trials as a target therapeutic for Parkinson's disease, its target pathway also implicated in tumorigenesis. As wa...
| Published: |
|
|---|---|
| Online Access: | http://hdl.handle.net/2047/D20001031 |